Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The input "losartan or nebivolol" refers to two distinct pharmaceutical drugs, losartan and nebivolol. Losartan is an angiotensin II receptor blocker (ARB) primarily used to treat hypertension, diabetic nephropathy, and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. It works by blocking the binding of angiotensin II to the AT1 receptor, which leads to vasodilation, decreased aldosterone secretion, and a reduction in blood pressure. Nebivolol is a beta-blocker, specifically a beta-1 selective adrenergic receptor blocker, that also exhibits nitric oxide-mediated vasodilation. It is used for the treatment of hypertension and heart failure. Its mechanism involves selectively blocking beta-1 adrenergic receptors, thereby reducing heart rate and myocardial contractility, and promoting vasodilation through the release of nitric oxide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on losartan or nebivolol.